




LYTHAM
PARTNERS
INVESTOR RELATIONS

Website design and development

Corporate website solutions for
small-cap companies





Your website is the most important communications tool for your business and for your investors.

- Each website project starts with a content strategy meeting.
- We work closely with your team to develop a custom website that effectively communicates your story.
- Investor relations sections are designed and developed to be fully compliant with SEC regulations and exchange rules.



We offer end-to-end website solutions for public companies.

- Intuitive design
- Mobile responsive
- Easy-to-use content management system
- Scalable platform
- Search Engine Optimization (SEO) tools
- Website analytics
- Ongoing maintenance options

MOLECULIN BIOTECH

BIOTECHNOLOGY

www.moleculin.com

[About](#) [Mission](#) [Technology](#) [Pipeline](#) [Partnerships](#) [Science](#) [News](#) [Investor](#)

[PANCREATIC CANCER](#) [ACUTE MYELOID LEUKEMIA](#) [BRAIN TUMORS](#) [SKIN CANCER](#)

Groundbreaking Cancer Therapies

PANCREATIC CANCER · GLOBLASTOMA BRAIN TUMORS
SKIN CANCER · ACUTE MYELOID LEUKEMIA

We are highly focused on developing treatments for highly resistant cancers. We are dedicated to dramatically changing the way these conditions are treated.

[LEARN MORE](#)

Technology

Potentially disruptive technologies

We have three highly differentiated technologies focused on next generation anthracycline, immune/transcription modulators and metabolism/glycosylation inhibitors. From those three core technologies, we have six potential oncology drug candidates.

[Learn More](#)

Targeted Indications

Attacking the most difficult cancers

We are developing treatments for rare and difficult cancers such as acute myeloid leukemia (AML), glioblastoma, brain tumors; cutaneous T-cell lymphoma (CTCL), a deadly form of skin cancer, and pancreatic cancer.

[Learn More](#)

Partnerships & Collaborations

Relationships with world-class cancer centers

Critical to our efforts is leveraging our continued collaborations and partnerships with leading cancer centers like MD Anderson Cancer Center, Emory University, the Mayo Clinic and others.

[Learn More](#)

[About](#) [Mission](#) [Technology](#) [Pipeline](#) [Partnerships](#) [Science](#) [News](#) [Investor](#)

[PANCREATIC CANCER](#) [ACUTE MYELOID LEUKEMIA](#) [BRAIN TUMORS](#) [SKIN CANCER](#)

Pancreatic Cancer

Together with our research partners we are working to develop a number of compounds that could have a profound impact on the treatment of pancreatic cancer in the coming years and provide hope to those that develop this disease.

[LEARN MORE](#)

[Pancreatic Cancer](#) [Acute Myeloid Leukemia](#) [Brain Tumors](#) [Skin Cancer](#) [Pipeline](#)

Pancreatic Cancer

Pancreatic cancer is an extremely dangerous disease, as it is generally not detectable in its early stages. And, when it does become apparent, it is highly resistant to currently available treatments.

[About](#) [Mission](#) [Technology](#) [Pipeline](#) [Partnerships](#) [Science](#) [News](#) [Investor](#)

[PANCREATIC CANCER](#) [ACUTE MYELOID LEUKEMIA](#) [BRAIN TUMORS](#) [SKIN CANCER](#)

Company Overview

We are highly focused on developing treatments for highly resistant cancers.

[TECHNOLOGY OVERVIEW](#) [PIPELINE & MILESTONES](#)

[Company Overview](#) [Mission](#) [Management](#) [Board of Directors](#) [Scientific Advisory Board](#)

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers.

We have three core technologies, all of which are based on discoveries made at M.D. Anderson Cancer Center by Dr. Wallace Priebe and his team. Our clinical stage drugs are Anemycin, a Next Generation Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML, and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML. We are also engaged in pre-clinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as Metabolism/Glycosylation inhibitors.

[Overview](#) [News / Events](#) [Financial Info](#) [Annual Report and Proxy](#) [Stock Data](#) [SEC Filings](#) [Governance](#) [Investor Tools](#)

[Email Alerts](#) [Text Alerts](#) [Comments](#) [Add News Feed](#)

Latest News

- Oct 15, 2019

Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery

HOUSTON, Oct. 15, 2019 /PRNewswire/ - Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or "we")

[Read More >](#)
- Aug 15, 2019

Moleculin Announces Completion of Lymphoma Trial Enrollment

HOUSTON, Aug. 15, 2019 /PRNewswire/ - Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or "we")

[Read More >](#)

Stock Information

October 4, 2019 12:22 PM EDT

Nasdaq MBRX	1.06	0.02 (1.92%)
SYMBOL	LAST	CHANGE
55.56k	0.7772 -3.15	1.04 -1.08
VOLUME	52 WEEK LOW/HIGH	DAY LOW/HIGH

Charting

Moleculin Biotech Inc.
NASDAQ Capital Market: MBRX

Frequency: 1Day
Events: [v] Price: [v] Volume: [v] Line: [v]

1D 5D 1M 3M 6M 1Y 2Y 5Y

Pipeline

Pre-Clinical | Clinical Preparation | Phase III | Collaboration

Acute Myeloid Leukemia (AML): Anemycin

[Anemycin](#) [Anemycin WP1066](#)

[MD Anderson Cancer Center](#)

Brain Tumors: WP1066 & WP122

[WP1066: Glioblastoma, medulloblastoma in the brain](#) [WP122: Oligodendroglioma, astrocytoma, glioblastoma](#)

[MD Anderson Cancer Center](#) [Duke University](#) [Emory University](#)

Pancreatic Cancer: WP1066 & WP122

[WP1066: Pancreatic cancer](#) [WP122: WP122: Pancreatic cancer](#)

Cutaneous T-Cell Lymphoma (CTCL): WP1220

[WP122: Cutaneous T-Cell Lymphoma](#)

[Duke University](#)

Ocular Tumors: WP1066

[WP1066: Ocular tumors](#)

[Next Generation Anthracycline](#) [Immune/Transcription Modulators](#) [Metabolism/Glycosylation Inhibitors](#) [Combination](#)

INVO BIOSCIENCE

MEDICAL DEVICES

www.invobioscience.com

S&W SEED COMPANY

AGRICULTURE

www.swseedco.com

Home About Us Our Products Sales & Distribution Research & Development Resources News Investors Contact Us

Alfalfa Sorghum Sunflower Corn Stevia Product Information

SEEDING THE WORLD

For more than 50 years we have been the #1 seed of the highest quality alfalfa.

- Alfalfa**
S&W offers the largest and most diverse offering of alfalfa seed varieties.
[Learn More](#)
- Sorghum**
Fast growing and high yielding hybrid sorghum varieties by S&W offer farmers unique yield performance.
[Learn More](#)
- Sunflower**
Proven top performing hybrid sunflower varieties to meet growers' expectations around the world.
[Learn More](#)
- Corn**
Works or use hybrid gene variety works well across multiple soil types.
[Learn More](#)
- Stevia**
Enhanced flavor profiles coupled with improved mechanical harvesting capabilities allow S&W's stevia varieties to rise above the rest.
[Learn More](#)

Our Vision

Our vision is to be the world's preferred proprietary seed company which supplies a range of forage, grain and specialty crop products that supports the growing global demand for animal proteins and healthier consumer diets.

[About Us](#)

Home About Us Our Products Sales & Distribution Research & Development Resources News Investors Contact Us

Alfalfa Sorghum Sunflower Corn Stevia Product Information

SEEDING THE WORLD

S&W Seed Company is a leading middle market agriculture company.

The Company's vision is to be the world's preferred proprietary seed company which supplies a range of forage, grain and specialty crop products that supports the growing global demand for animal proteins and healthier consumer diets.

Listen to the S&W Seed Company fiscal year 2019 conference call

Company Contact

Matthew Szec
Chief Financial Officer
msz@swseedco.com
(855) 884-2538

Investor Contact

Lytham Partners
lsp@lythampartners.com
(602) 889-9700

Investor Links

- Investor Home
- Investor Dashboard
- Press Releases
- Events & Presentations
- Conference Calls
- Analyst Coverage
- Stock Chart

To Our Loyal Shareholders

S&W Seed Company is committed to developing best in class hybrids and varieties across a platform of forage and specialty crop products that meet the needs of the men and women that work so hard every day to feed a burgeoning global population. We are committed to develop hybrids and varieties that improve yields, not only on good soil conditions, but in highly saline and drought stricken regions. We are committed to ensuring that our products are resistant to diseases and insects that pose farmers problems, while ensuring enhanced digestibility for livestock producers. Where appropriate, we are committed to developing crops that are resistant to certain herbicides allowing farmers to enhance their overall productivity. Ultimately, we are committed to the success of agriculture—across all of its spectrum—which is the backbone for which all of us depend upon so dearly each and every day.

Please read our 2018 Annual Report to see how S&W continues to evolve

Events & Presentations

S&W Fourth Quarter & Fiscal Year 2019 Financial Results Conference Call

[Listen to Webcast](#) [View Press Release](#) [View Transcript](#)

S&W Discusses Agreement with Corteva Agriscience™, Agriculture Division of DowDuPont

[Listen to Webcast](#) [View Presentation](#)

Home About Us Our Products Sales & Distribution Research & Development Resources News Investors Contact Us

Alfalfa Sorghum Sunflower Corn Stevia Product Information

ALFALFA

Focuses on high yields and forage quality in your growing environment

Request a Product Sheet

Alfalfa Varieties

View 2018 Diversity that feeds for S&W Seed Varieties

Our specialty in high-yield alfalfa varieties with a wide range of adaptation across many growing environments. Our non-dormant breeding program is focused on maximizing yield regardless of soil and water salinity. Our dormant alfalfa breeding emphasizes high yield and forage quality, developing hardy alfalfa varieties with plenty of resistance to disease and stress.

- SW227**
First & 2nd year harvest
Late flowering, high plant vigor, extensive rooting & branching
- SW201**
First & 2nd year harvest
Optimal overwintering, green growth and late flowering
- SW10**
Dormancy 10
Excellent yielding variety non-dormant variety
- SW9720**
Dormancy 10
A high yielding non-dormant tolerant variety
- SW9628**
Dormancy 10
Very high yielding variety non-dormant variety
- SW9215**
Dormancy 10
High yielding non-dormant tolerant variety
- SW9215RRS**
Dormancy 10
High yielding variety non-dormant variety
- SW8421S**
Dormancy 10
High yielding variety non-dormant variety
- SW7410**
Dormancy 10
High yielding variety non-dormant variety
- SW6330**
Dormancy 10
High yielding variety non-dormant variety

Home About Us Our Products Sales & Distribution Research & Development Resources News Investors Contact Us

Alfalfa Sorghum Sunflower Corn Stevia Product Information

RESEARCH & DEVELOPMENT

We are focused on building and integrating seed technology platforms that can bring significant value to our customers.

We continue to analyze the markets to better understand the traits that we believe will be most desirable to our customers.

Request a Product Sheet

Research & Development

- GENE-EDITED ALFALFA PLANT**
Calyx and S&W's Gene-Edited Alfalfa Plant Designated as Non-Regulated by USDA
- EXPANDS FOCUS IN HYBRID CROPS**
S&W Seed Company Expands Focus in Hybrid Crops with Appointment of David Callachor
- GENERIC GENETICS AGREEMENT**
S&W Enters Alfalfa Seed Development Agreement with Genetic Genetics

IMMUCELL CORPORATION

ANIMAL HEALTH

www.immuCell.com

ImmuCell About ImmuCell First Defense Re-Tain Sales & Distributors Resources News Investors

207.878.2770 mail@immucell.com

Delivering Immediate Immunity™ to newborn calves.

First Defense® Tri-Shield™

First Defense® Tri-Shield™ is the only USDA accredited, colostrum derived, scours preventative providing immediate immunity™ against E. coli, coronavirus and rotavirus (three main causes of neonatal scours). Scours is the primary cause of death in newborn calves. Calves that survive scours are highly susceptible to respiratory and other secondary diseases along with stunted growth and production losses. Scours is a serious economic drain for both the dairy and beef industry.

Re-Tain™ Purified Nisin Intramammary Treatment

ImmuCell is nearing FDA approval of Re-Tain™, an intramammary treatment for subclinical mastitis. Mastitis is the most costly and common disease affecting the dairy industry inflicting a drain in profits of approximately \$2 billion each year. This tool significantly differs from traditional antibiotics, will not require a milk discard or meat withhold, and will allow for economically justified treatment of mastitis prior to seeing clinical signs.

Sales & Distributors

Locate your regional sales representative or distributor.

ImmuCell About ImmuCell First Defense Re-Tain Sales & Distributors Resources News Investors

207.878.2770 mail@immucell.com

OUR PURPOSE

- We are dedicated to providing cost-effective solutions to dairy and beef producers to maximize the health and welfare of their respective productive assets – their dairy and beef calves and their milk producing cows.
 - Our First Defense® Tri-Shield™ product protects newborn dairy and beef calves against the harmful pathogens, E. coli, coronavirus, and rotavirus that can cause bovine enteritis, or calf scours, that can dramatically hinder a calf's ability to reach its maximum product capacity or cause death.
 - Re-Tain™, our purified Nisin intramammary treatment, nearing completion of the FDA approval process, will treat subclinical mastitis (infection of the mammary gland) in milk producing cows. Mastitis is the most costly and common disease affecting the dairy industry, with an annual impact of approximately \$2 billion.
- Our products are designed to treat infections in calves and cows without the use of traditional antibiotics used in human healthcare, thereby reducing the amount of antibiotics in the human food chain, that have given rise to incidence of life-threatening human infections from antibiotic-resistant bacteria, commonly known as "superbugs."

Contact Us

16 Deerpark Drive
Portland, ME 04103

Office: 207.878.2770
Sales: 1.800.388.5222
mail@immucell.com

NASDAQ: ICCC

Recent News

08-17-19 ImmuCell Enters into Lease Agreement for a Facility to Expand First Defense® Production Capacity

08-11-19 ImmuCell Announces an Agreement Covering the Formulation and Aesthetic Filing of "Nippon" for Re-Tain™

08-29-19 ImmuCell Receives FDA Response to First CMC Submission for Re-Tain™

08-12-19 ImmuCell Announces Unaudited Financial Results for Second Quarter of 2019

Follow Us

f t

Copyright © 2019 ImmuCell Corporation. Home About ImmuCell First Defense Re-Tain Sales & Distributors Resources News Investors Contact Us

Who is ImmuCell?

ImmuCell is an entrepreneurial animal health company that develops, manufactures and markets scientifically-proven products that maximize the genetic potential of dairy and beef through disease prevention, and reduced dependence on antibiotics.

What is Our Philosophy?

At ImmuCell we have a desire to make life easier and business more profitable for dairy and beef producers. We hate fluff so we are committed to meeting USDA, CFIA, FDA, and OMRI standards for efficacy. We also hate inflated prices to cover bureaucratic overhead which is why we run lean, logical, committed to our customers and results.

Why Choose ImmuCell?

ImmuCell holds a unique position, they are the only animal health company with the ability to concentrate, purify, and quantify specific colostrum antibodies (E. coli, coronavirus, and rotavirus) on a commercial scale. This has resulted in products to treat one of the two most frustrating problems within commercial beef and dairy operations – calf scours. The second most frustrating problem, Mastitis, is something ImmuCell is also aiming to solve – with their ability to purify nisin for intramammary applications.

How To Administer a First Defense

First Defense: RFDTV & D...

First Defense: Vir-Clar Da...
Scours rate down by about 75%

What people are saying about First Defense®

"When first approached about using First Defense® I wasn't quite sure about it but, it's a simple easy way as far as prevention for scours. It's something we can give day old, immediately and see the benefits right away."

BRAD SCOTT
Scott Brothers Dairy | Moreno Valley, CA

"We have been using First Defense® for the last 3-4 years and are really happy with the product. For us it's important, it's a big investment and a huge return. The product is convenient and versatile. Knowing we have protection as soon as the calf hits the ground is satisfying and comforting. This product gives assurance."

DAN KULLOT, DVM
Syracuse Dairy | Syracuse, KS

ImmuCell About ImmuCell First Defense Re-Tain Sales & Distributors Resources News Investors

207.878.2770 mail@immucell.com

FIRST DEFENSE® TRI-SHIELD™ AND FIRST DEFENSE FOR SCOURS

First Defense® Tri-Shield™, approved by the USDA in November 2017, combines the E. coli and coronavirus antibodies contained in First Defense®, with rotavirus antibody content to produce the only product on the market with trivalent protection against three of the leading pathogens that lead to calf scouring. Preventing scours in newborn calves reduces the need to use treatment antibiotics later in life. This new product will be available in a gel tube delivery format.

First Defense® is the only USDA-licensed, orally delivered scours preventive product on the market for calves with claims against E. coli K89 and coronavirus (two leading causes of scours).

First Defense® products provide bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Our milk antibody products provide Immediate Immunity™ during the first few critical days of life when calves need this protection most.

Studies have shown that calves that scour are more susceptible to other diseases later in life and under-perform calves that do not contract scours. The direct, two-part mode-of-action of First Defense® delivers specific immunoglobulins at the gut level to immediately protect against disease, while also providing additional antibodies that are absorbed into the bloodstream. These circulating antibodies function like a natural timed-release mechanism, as they are re-secreted into the gut later to provide extended protection. A single dose of First Defense® products provide a guaranteed level of protection proven to reduce mortality and morbidity from two major causes of calf scours.


PARTNERING WITH THE NEXT GENERATION OF INNOVATORS

PHOENIX

3800 N. Central Avenue
Suite 750
Phoenix, AZ 85012
Office 602.889.9700
www.lythampartners.com

NEW YORK

245 Park Avenue
39th Floor
New York, NY 10167
Office 646.829.9700
info@lythampartners.com



LYTHAM
PARTNERS
INVESTOR RELATIONS